{"relation": [["", "ABC/3TC + ATV/r: Induction Phase", "ABC/3TC + ATV: Randomization Phase", "ABC/3TC + ATV/r: Randomization Phase", "ABC/3TC + ATV: Extension Phase", "ABC/3TC + ATV/r: Extension Phase"], ["Description", "Abacavir (ABC) 600 milligrams (mg)/lamivudine (3TC) 300 mg fixed-dose combination tablet (FDC) once a day (QD) plus atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD during the first 36 weeks of the study (planned interim analysis)", "Simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with 400 mg ATV QD", "Continuation of ABC/3TC FDC tablet administered QD for an additional 48 weeks in combination with ATV/r QD", "Simplification regimen of the ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV QD", "Continuation of ABC/3TC FDC tablet administered QD for an additional 60 weeks in combination with ATV/r QD"]], "pageTitle": "Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00440947?sect=X056&view=results", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 3, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042986646.29/warc/CC-MAIN-20150728002306-00132-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 865861775, "recordOffset": 865845381, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Reporting Groups The study had a 36-week Non-randomized Induction Phase, followed by an 84-week Randomized Phase. All PAR completing 84 weeks were eligible to enter an optional 60-week extension phase (EP); some PAR chose not to continue in the EP. PAR whose HIV-RNA wasn't <50 copies/ml before Week 36 weren't allowed to randomize at Week 36 and were withdrawn. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants (PAR) were recruited at 66 centers in the United States of America and Canada. HIV-RNA, human immunodeficiency virus-ribonucleic acid; ml, milliliters. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r) Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)", "textAfterTable": "Participant Flow for 3 periods Period 1: \u00a0 36-Week Induction Phase \u00a0 \u00a0 ABC/3TC + ATV/r: Induction Phase \u00a0 \u00a0 ABC/3TC + ATV: Randomization Phase \u00a0 \u00a0 ABC/3TC + ATV/r: Randomization Phase \u00a0 \u00a0 ABC/3TC + ATV: Extension Phase \u00a0 \u00a0 ABC/3TC + ATV/r: Extension Phase \u00a0 STARTED \u00a0 \u00a0 515 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 442 [1] \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 NOT COMPLETED \u00a0 \u00a0 73 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0", "hasKeyColumn": false, "keyColumnIndex": -1, "headerRowIndex": 0}